UPDATE 4-Loxo signs lucrative cancer drug deal with Bayer, but shares fall
November 14, 2017 at 12:10 PM EST
Nov 14 (Reuters) - Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.
